# DESCRIPTION

## FIELD OF THE INVENTION

- introduce field of cancer therapy

## BACKGROUND OF THE INVENTION

- summarize chemokines and their receptors
- discuss CXCR4 and CCL20 in cancer development

## SUMMARY OF THE INVENTION

- introduce CCL20 neutralizing agents for cancer treatment
- describe anti-CCL20 antibodies as anti-cancer agents
- outline therapeutic methods using CCL20-neutralizing antibodies

## DETAILED DESCRIPTION OF THE INVENTION

- introduce anti-CCL20 antibodies for cancer treatment
- describe method for treating CCL20 dependent cancer
- outline various embodiments of cancer treatment
- describe pharmaceutical composition for cancer treatment
- outline various embodiments of pharmaceutical composition
- describe kit for cancer treatment
- define antibodies and their components
- describe antigen binding domains and epitopes
- outline methods for generating monoclonal and polyclonal antibodies
- describe antibody fragments and their production
- introduce human antibodies
- describe production of humanized antibodies
- define specific binding
- describe CCL20-neutralizing antibodies
- describe pharmaceutical compositions
- formulate pharmaceutical compositions
- administer pharmaceutical compositions
- describe therapeutic use
- determine effective dosage
- describe treatment of cancer
- describe administration routes
- provide examples of cancer treatment

## EXAMPLES

### Experimental Procedures

- describe cell culture
- detail transduction of cell lines and single-cell clone production
- outline immunohistochemistry and scoring
- explain RNA extraction and reverse transcription
- describe semi-quantitative PCR and real-time PCR
- detail various cell assays and MRI analysis

### Example 1

- characterize CCL20 and CCR6 expression in prostate cell lines
- investigate CCL20-mediated activation in PC3 cells
- test adhesion of PC3 cells to ECM proteins
- examine CCL20 expression in other human cancer cell lines

### Example 2

- determine role of CCL20 in tumor development in vivo using tumor xenograft model

### Example 3

- evaluate effect of neutralizing antibodies to human CCL20 on growth of CCL20-and CXCR4 overexpressing PC3 cells

### Example 4

- evaluate expression of CCL20 and CCR6 in human prostate cancer tissues

